Advances in the control of chemotherapy-induced emesis

E. A. Perez, D. R. Gandara

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cancer patients consistently rank nausea and vomiting as the most feared side effects of treatment. Cisplatin, one of the most active chemotherapeutic agents, causes acute emesis and a delayed emesis syndrome, which also results in considerable patient morbidity. Despite the use of metoclopramide-containing combination regimens, approximately one third of cisplatin-treated patients continue to experience emesis. In recent years, considerable progress has been made in managing chemotherapy-induced emesis. This review discusses several factors that have contributed to improved antiemetic control, including standardization of antiemetic trial methodology, insight into the pathogenesis of chemotherapy-induced emesis, and the development of a new class of antiemetic agents, the serotonin antagonists. In clinical studies performed to date, these agents have generally proven to be both effective and safe. Three multicenter trials of the selective serotonin antagonist ondansetron in the prevention of nausea and vomiting from cisplatin are reviewed.

Original languageEnglish (US)
Pages (from-to)47-50
Number of pages4
JournalAnnals of Oncology
Volume3
Issue numberSUPPL. 3
StatePublished - 1992
Externally publishedYes

Fingerprint

Vomiting
Drug Therapy
Antiemetics
Cisplatin
Serotonin Antagonists
Nausea
Ondansetron
Metoclopramide
Multicenter Studies
Morbidity
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Perez, E. A., & Gandara, D. R. (1992). Advances in the control of chemotherapy-induced emesis. Annals of Oncology, 3(SUPPL. 3), 47-50.

Advances in the control of chemotherapy-induced emesis. / Perez, E. A.; Gandara, D. R.

In: Annals of Oncology, Vol. 3, No. SUPPL. 3, 1992, p. 47-50.

Research output: Contribution to journalArticle

Perez, EA & Gandara, DR 1992, 'Advances in the control of chemotherapy-induced emesis', Annals of Oncology, vol. 3, no. SUPPL. 3, pp. 47-50.
Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Annals of Oncology. 1992;3(SUPPL. 3):47-50.
Perez, E. A. ; Gandara, D. R. / Advances in the control of chemotherapy-induced emesis. In: Annals of Oncology. 1992 ; Vol. 3, No. SUPPL. 3. pp. 47-50.
@article{7312ab2b0ef246f68130b15dddd7c196,
title = "Advances in the control of chemotherapy-induced emesis",
abstract = "Cancer patients consistently rank nausea and vomiting as the most feared side effects of treatment. Cisplatin, one of the most active chemotherapeutic agents, causes acute emesis and a delayed emesis syndrome, which also results in considerable patient morbidity. Despite the use of metoclopramide-containing combination regimens, approximately one third of cisplatin-treated patients continue to experience emesis. In recent years, considerable progress has been made in managing chemotherapy-induced emesis. This review discusses several factors that have contributed to improved antiemetic control, including standardization of antiemetic trial methodology, insight into the pathogenesis of chemotherapy-induced emesis, and the development of a new class of antiemetic agents, the serotonin antagonists. In clinical studies performed to date, these agents have generally proven to be both effective and safe. Three multicenter trials of the selective serotonin antagonist ondansetron in the prevention of nausea and vomiting from cisplatin are reviewed.",
author = "Perez, {E. A.} and Gandara, {D. R.}",
year = "1992",
language = "English (US)",
volume = "3",
pages = "47--50",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Advances in the control of chemotherapy-induced emesis

AU - Perez, E. A.

AU - Gandara, D. R.

PY - 1992

Y1 - 1992

N2 - Cancer patients consistently rank nausea and vomiting as the most feared side effects of treatment. Cisplatin, one of the most active chemotherapeutic agents, causes acute emesis and a delayed emesis syndrome, which also results in considerable patient morbidity. Despite the use of metoclopramide-containing combination regimens, approximately one third of cisplatin-treated patients continue to experience emesis. In recent years, considerable progress has been made in managing chemotherapy-induced emesis. This review discusses several factors that have contributed to improved antiemetic control, including standardization of antiemetic trial methodology, insight into the pathogenesis of chemotherapy-induced emesis, and the development of a new class of antiemetic agents, the serotonin antagonists. In clinical studies performed to date, these agents have generally proven to be both effective and safe. Three multicenter trials of the selective serotonin antagonist ondansetron in the prevention of nausea and vomiting from cisplatin are reviewed.

AB - Cancer patients consistently rank nausea and vomiting as the most feared side effects of treatment. Cisplatin, one of the most active chemotherapeutic agents, causes acute emesis and a delayed emesis syndrome, which also results in considerable patient morbidity. Despite the use of metoclopramide-containing combination regimens, approximately one third of cisplatin-treated patients continue to experience emesis. In recent years, considerable progress has been made in managing chemotherapy-induced emesis. This review discusses several factors that have contributed to improved antiemetic control, including standardization of antiemetic trial methodology, insight into the pathogenesis of chemotherapy-induced emesis, and the development of a new class of antiemetic agents, the serotonin antagonists. In clinical studies performed to date, these agents have generally proven to be both effective and safe. Three multicenter trials of the selective serotonin antagonist ondansetron in the prevention of nausea and vomiting from cisplatin are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0026770067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026770067&partnerID=8YFLogxK

M3 - Article

C2 - 1390317

AN - SCOPUS:0026770067

VL - 3

SP - 47

EP - 50

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 3

ER -